H.C. Wainwright initiates coverage of Skye Bioscience with 'buy' rating

Skye Bioscience

30/09/2025 12:48

** Brokerage H.C. Wainwright initiates coverage on Skye Bioscience SKYE.O with "buy" rating, on safety and staying power expectations of Skye's weight loss drugs

** Shares of SKYE were up 3.1% at $4 premarket

** HCW sets $20 PT, saying the biopharmaceutical company's experimental drug nimacimab is a safe GLP-1 add-on enabling longer use at lower doses

** "Largely cushioned downside, small positive data could lift shares, and strong results make nimacimab a major obesity add-on", says H.C. Wainwright

** All the seven analysts covering the stock have a "buy" or higher rating; median PT is $14.50 - LSEG data

** As of last close, SKYE stock is up 37.1% YTD

 (Reporting by Anuj T in Bengaluru)

 ((anuj.t@thomsonreuters.com))